Citius Oncology Inc. (CTOR)
Citius Oncology Statistics
Share Statistics
Citius Oncology has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 303 |
| FTD / Avg. Volume | 0.31% |
Short Selling Information
The latest short interest is 31.75K, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 31.75K |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 0.37 |
Valuation Ratios
The PE ratio is -4.7 and the forward PE ratio is null. Citius Oncology's PEG ratio is 0.06.
| PE Ratio | -4.7 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 2.16 |
| P/FCF Ratio | -20.41 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Citius Oncology Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.34, with a Debt / Equity ratio of 0.08.
| Current Ratio | 0.34 |
| Quick Ratio | 0.08 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.61 |
| Cash Flow / Debt | 0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.46% and return on capital (ROIC) is -42.35%.
| Return on Equity (ROE) | -0.46% |
| Return on Assets (ROA) | -0.25% |
| Return on Capital (ROIC) | -42.35% |
| Revenue Per Employee | $undefined |
| Profits Per Employee | $undefined |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 576K |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -0.63, so Citius Oncology's price volatility has been lower than the market average.
| Beta | -0.63 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 27.43 |
| Average Volume (20 Days) | 98.23K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -20.57M |
| Net Income | -21.15M |
| EBITDA | -20.57M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.3 |
Balance Sheet
The company has 112 in cash and 3.8M in debt, giving a net cash position of -3.8M.
| Cash & Cash Equivalents | 112 |
| Total Debt | 3.8M |
| Net Cash | -3.8M |
| Retained Earnings | -39.28M |
| Total Assets | 90.48M |
| Working Capital | -26.32M |
Cash Flow
In the last 12 months, operating cash flow was 126.35K and capital expenditures -5M, giving a free cash flow of -4.87M.
| Operating Cash Flow | 126.35K |
| Capital Expenditures | -5M |
| Free Cash Flow | -4.87M |
| FCF Per Share | -0.07 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -49.18% |
| FCF Yield | -11.17% |
Analyst Forecast
The average price target for CTOR is $4.5, which is 637.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.5 |
| Price Target Difference | 637.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -0.76 |
| Piotroski F-Score | 3 |